Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

NCT00845650 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

129

Enrollment

INDUSTRY

Sponsor class

Conditions

Anthrax

Interventions

BIOLOGICAL: AIGIV 3.5 mg/kg
BIOLOGICAL: Gamunex 90 mg/kg
BIOLOGICAL: AIGIV 7.0 mg/kg
BIOLOGICAL: Gamunex 180 mg/kg
BIOLOGICAL: AIGIV 14.0 mg/kg
BIOLOGICAL: Gamunex 360 mg/kg

Sponsor

Emergent BioSolutions

Collaborators

[object Object]